Omvoh FDA approval for Crohn's IL-23p19 inhibitor therapy - Drug Discovery and Development
New FDA approval adds another IL‑23p19 biologic option for moderate‑to‑severe Crohn’s disease and highlights two‑year efficacy data, which may affect treatment choices and future pediatric availability.